Hepatitis A
Also known as: HAV
Methodology & AI Transparency ⓘ
Hepatitis A Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is hepatitis? Hepatitis is inflammation of the liver .
- 2 Real-world patient consensus: Mapped to Liver, Gallbladder & Pancreatic Health under ICD-10-CM B15.9 for Hepatitis A clinical workups.
- 3 Typical cash cost range: Workup highlights for Hepatitis A (B15.9): metabolic insulin-sensitizing weight in Hepatitis A (B15.9: optimization).
- 4 Top reported side effects / signs: Longitudinal Hepatitis A monitoring tracks Total Bilirubin & in Hepatitis A (B15.9: Albumin) toward Bilirubin 0.2–1.2 mg/dL; Albumin >= 4.0 g/dL (B15.9).
Ask our AI Specialists anything about Hepatitis A
What Is Hepatitis A?
What is hepatitis? Hepatitis is inflammation of the liver . Inflammation is swelling that happens when tissues of the body are injured or infected. It can damage your liver. This swelling and damage can affect how well your liver functions. What is hepatitis A? Hepatitis A is a type of viral hepatitis. It causes an acute, or short-term, infection. This means that people usually get better without treatment after a few weeks. Thanks to a vaccine, hepatitis A is not very common in the United States. What causes hepatitis A? Hepatitis A is caused by the hepatitis A virus. The virus spreads through contact with an infected person's stool.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Hepatitis A (B15.9) center on or biliary cholesterol in Hepatitis A (B15.9: supersaturation). Cross-referenced with NIH MeSH (Hepatitis A), targeted liver & hepatology interventions aim to normalize Total Bilirubin & in Hepatitis A (B15.9: Albumin).
Common Symptoms & Clinical Signs
- • Eat food made by someone who has the virus and did not properly wash their hands after using the bathroom
- • Drink contaminated water or eat foods that were rinsed with contaminated water
- • Presentation of Hepatitis A (B15.9): unexplained fatigue, pruritus [Hepatitis A B15.9]
- • Secondary Hepatitis A clinical sign: epigastric pain, steatorrhea [Hepatitis A B15.9]
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hepatitis A Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B15.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Liver, Gallbladder & Pancreatic Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Total Bilirubin & in Hepatitis A (B15.9: Albumin) | Bilirubin 0.2–1.2 mg/dL; Albumin >= 4.0 g/dL (B15.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipase & in Hepatitis A (B15.9: Triglycerides) | Normal enzymatic baseline (B15.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT, AST, Alkaline in Hepatitis A (B15.9: Phosphatase & GGT) | ALT < 25 U/L (men) / < 19 U/L (women) (B15.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hepatitis A
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Elbasvir and Grazoprevir Zepatier • RxCUI 1734636 | Hepatitis C Virus NS5A Inhibitor | 84% | $0.9200 | $ 45.76 /mo |
| Cimduo (Lamivudine and Tenofovir Disoproxil Fumarate) Cimduo • RxCUI 2003255 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 75% | $0.2339 | $ 25.34 /mo |
| Tenofovir Disoproxil Fumarate Tablets Tenofovir Disoproxil Fumarate Tablets Generic • RxCUI RXN-62135466-2958 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 76% | $0.2938 | $ 20.40 /mo |
| Vemlidy (Tenofovir Alafenamide) Vemlidy • RxCUI RXN-B619582301 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 77% | $49.0404 | $ 640.00 /mo |
| Epivir (Lamivudine) Epivir • RxCUI 199147-B49702205 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 87% | $0.2339 | $ 12.80 /mo |
| Nabi-Hb (Hepatitis B Immune Globulin (Human)) Nabi-Hb • RxCUI 1658127 | Human Immunoglobulin | 83% | $0.9900 | $ 79.78 /mo |
| Mavyret (Glecaprevir and Pibrentasvir) Mavyret • RxCUI RXN-B00742625 | Hepatitis C Virus NS3/4A Protease Inhibitor | 80% | $152.8336 | $ 640.00 /mo |
| Combivir (Lamivudine and Zidovudine) Combivir • RxCUI 200082-B49702202 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 79% | $0.2339 | $ 13.61 /mo |
| Zepatier (Elbasvir and Grazoprevir) Zepatier • RxCUI 1734642 | Hepatitis C Virus NS5A Inhibitor | 92% | $3.4900 | $ 259.78 /mo |
| Harvoni (Ledipasvir and Sofosbuvir) Harvoni • RxCUI RXN-B619581803 | Hepatitis C Virus NS5A Inhibitor | 86% | $3.0900 | $ 230.98 /mo |
| Hepatitis B Immune Globulin (Human) Nabi-Hb • RxCUI 1658125 | Human Immunoglobulin | 91% | $1.3600 | $ 63.58 /mo |
| Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) Vosevi • RxCUI RXN-B619582401 | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor | 74% | $278.3091 | $ 640.00 /mo |
| Tenofovir Alafenamide Vemlidy • RxCUI RXN-619582301-2546 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 79% | $49.0404 | $ 185.00 /mo |
| Ledipasvir and Sofosbuvir Harvoni • RxCUI RXN-619581803-2954 | Hepatitis C Virus NS5A Inhibitor | 91% | $0.9600 | $ 47.38 /mo |
| Entecavir Anhydrous Baraclude • RxCUI RXN-42494458-1840 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 91% | $0.3119 | $ 28.39 /mo |
| Sofosbuvir Sovaldi • RxCUI RXN-619581501-2393 | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor | 77% | $278.3091 | $ 185.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hepatitis A)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic: What a 2,178-Participant Study Found This study evaluated the efficacy of GLP-1RAs in patients with NAFLD and NASH. Primary care diabetes • 2024-06-15 • Meta-Analysis | N = 2,178 | 99/100 | PMID 38555202 ↗ |
| New Insights on Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated: What a 1,197-Participant Study Found In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. The New England journal of medicine • 2025-06-05 • Phase III Randomized Trial | N = 1,197 | 96/100 | PMID 40305708 ↗ |
| New Insights on Long-term protection from naturally acquired immunity against hepatitis E virus: What a 3,194-Participant Study Found Six were hospitalized, all of whom were baseline seronegative. Nature communications • 2025-12-17 • Phase III Randomized Trial | N = 3,194 | 96/100 | PMID 41407683 ↗ |
| New Insights on Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic: What a 1,778-Participant Study Found This study did not demonstrate the efficacy of CVC for treating liver fibrosis assessed by histology in adults with NASH; however, CVC was safe and well tolerated in patients with NASH and liver fibrosis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2024-01-15 • Phase III Randomized Trial | N = 1,778 | 96/100 | PMID 37061109 ↗ |
| New Insights on Eight-year real-world benefits and safety of tenofovir alafenamide for treatment: What a 866-Participant Study Found Long-term TAF treatment exhibited favourable safety and tolerability with high rates of viral suppression and no development of resistance. Alimentary pharmacology & therapeutics • 2024-12-15 • Phase III Randomized Trial | N = 866 | 93/100 | PMID 39327857 ↗ |
Hepatitis A Patient Community & “People Like Me” Threads
Filter Hepatitis A community threads and patient logs by age, biological sex, dosage, and treatment duration.